Female fertility preservation: Impact of cancer on ovarian function and oocyte quality

Fabiani, Cristina; Ferrante, Maria Giulia; Meneghini, C; Licata, Emanuele; Paciotti, G; Gallo, Mariagrazia; Schiavi, Michele Carlo; Spina, Vincenzo; Guarino, Antonella; Caserta, Donatella; Rago, Rocco

doi:10.1002/ijgo.13702

Cited by 11 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, our univariate and the multivariate analysis identified that cancer is the only risk factor for the presence of dysmorphic oocytes in BC patients. However, these women did not have a compromised ovarian reserve in agreement with the results of several authors [ 6 , 9 , 14 , 29 , 30 ]. In contrast to our results, Quinn et al showed that breast cancer diagnosis is not associated with a decreased maturity rate of retrieved oocytes compared with patients undergoing elective fertility preservation for male factor [ 8 ].…”

Section: Discussionsupporting

confidence: 91%

Oocyte Quality Assessment in Breast Cancer: Implications for Fertility Preservation

Fabiani

Guarino

Meneghini

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the effects of breast cancer on the ovarian response and on oocyte quality following controlled ovarian hyperstimulation (COH). Methods: This retrospective case-control study evaluated the effects of breast cancer on the ovarian response and on the oocyte quality. Oncological patients with breast cancer undergoing controlled ovarian stimulation cycles for fertility preservation, and age- and date-matched controls undergoing COH for in vitro fertilization (IVF) for male or tubal factor infertility were included in the study. Two hundred and ninety-four women were enrolled: 105 affected by breast cancer and 189 healthy women in the control group. Both groups were comparable in terms of age, BMI, and AMH value. Maximal estradiol levels on the triggering day, duration of stimulation, total amount of gonadotropins administered, number of oocytes retrieved, rate of metaphase 2 oocyte production, and numbers of immature and dysmorphic oocytes were analyzed. Results: Considering factors influencing the oocyte quality, such as age, BMI, AMH, duration of stimulation, E2 level on the triggering day, total FSH cumulative dose, stage, histotype, BRCA status, and hormone receptors, the univariate and multivariate analyses identified breast cancer as a risk factor for the presence of dysmorphic oocytes. Conclusions: The diagnosis of breast cancer does not seem to be associated with the impairment of the ovarian reserve, but is linked to a worsening oocyte quality.

show abstract

Section: Discussionsupporting

confidence: 91%

Oocyte Quality Assessment in Breast Cancer: Implications for Fertility Preservation

Fabiani

Guarino

Meneghini

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…The clinical features of all the subjects are shown in Table 1 . Only estradiol resulted significantly different ( p < 0.05) in the two groups with lower levels observed in BC women thanks to the administration of aromatase inhibitors (letrozole) in women with hormone-sensitive breast cancer [ 13 ]. No other significant differences in clinical parameters were found.…”

Section: Resultsmentioning

confidence: 99%

“…BC is one of the oncological pathologies for which is indicated fertility preservation [ 7 ], a type of procedure often applied in oncology to give an opportunity to cancer survivors to maintain reproductive health and have children after oncologic treatment [ 8 , 9 , 10 ]. Chemotherapy, radiotherapy, surgery or a combination thereof expose women of reproductive age to risk of damage to the ovary, increase the risks of premature ovarian failure (POF), early menopause, ovarian endocrine disorders, and infertility [ 11 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

A Pilot Study on Biochemical Profile of Follicular Fluid in Breast Cancer Patients

et al. 2023

View full text Add to dashboard Cite

Breast cancer (BC) is the most common type of cancer among women in almost all countries worldwide and is one of the oncological pathologies for which is indicated fertility preservation, a type of procedure used to help keep a person’s ability to have children. Follicular fluid (FF) is a major component of oocyte microenvironment, which is involved in oocyte growth, follicular maturation, and in communication between germ and somatic cells; furthermore, it accumulates all metabolites during oocytes growth. To obtain information about changes on fertility due to cancer, we aimed at investigating potential biomarkers to discriminate between FF samples obtained from 16 BC patients and 10 healthy women undergoing in vitro fertilization treatments. An NMR-based metabolomics approach was performed to investigate the FF metabolic profiles; ELISA and western blotting assays were used to investigate protein markers of oxidative and inflammatory stress, which are processes closely related to cancer. Our results seem to suggest that FFs of BC women display some significant metabolic alterations in comparison to healthy controls, and these variations are also related with tumor staging.

show abstract

“…Oocyte CLCG is one of the common oocyte morphological abnormalities, and the cause and mechanism of its formation are still unclear (17)(18)(19)(20). Studies revealed that in the natural cycle, the maturation of the oocyte nucleus and cytoplasm often occurs synchronously, but the development of the two may be asynchronous in the ovulation cycle (21)(22)(23).…”

Section: Discussionmentioning

confidence: 99%

Effects of Oocyte Cytoplasmic Central Granulation on Embryonic Development, Blastocyst Formation, and Pregnancy Outcome in Assisted Reproductive Technology and Its Mechanism

Zhang¹,

Zeng²,

Liu³

et al. 2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

To investigate whether oocyte centrally located cytoplasmic granulation (CLCG) affects embryonic development, blastocyst formation, and pregnancy outcomes in assisted reproductive technology, fifty patients with CLCG in all oocytes were selected as the CLCG group. Then, 150 patients with no abnormal oocyte morphology were randomly recruited as the control group. Both groups underwent laparoscopy, hysterosalpingography (HSG), vaginal ultrasound, and male semen examination. The down-regulation regimen was selected regarding the patient's ovarian reserve. The egg maturation rate, normal fertilization rate, cleavage rate, available embryo rate, and high-quality embryo rate in the CLCG group were greatly inferior to those in the control group, with remarkable differences (P< 0.05). CLCG grading of oocytes after 30 cycles in the CLCG group indicated that there were 36 cases in the mild group and 14 cases in the severe group. The egg maturation rate in the mild group was lower than that in the severe group, with a notable difference (P< 0.05). The fertilization rate, cleavage rate, available embryo rate, and high-quality embryo rate in the mild group were higher than those in the severe group, with a notable difference (P< 0.05). Compared with the control group, there was no considerable difference in the implantation rate, clinical pregnancy rate, and abortion rate between the CLCG group (P> 0.05). In summary, oocyte CLCG may affect fertilization, embryonic development, and blastocyst formation, but not pregnancy outcomes

show abstract

Female fertility preservation: Impact of cancer on ovarian function and oocyte quality

Cited by 11 publications

References 24 publications

Oocyte Quality Assessment in Breast Cancer: Implications for Fertility Preservation

Oocyte Quality Assessment in Breast Cancer: Implications for Fertility Preservation

A Pilot Study on Biochemical Profile of Follicular Fluid in Breast Cancer Patients

Effects of Oocyte Cytoplasmic Central Granulation on Embryonic Development, Blastocyst Formation, and Pregnancy Outcome in Assisted Reproductive Technology and Its Mechanism

Contact Info

Product

Resources

About